RVPH: Brilaroxazine: Multi-receptor Modulator on Deck

Another med.

Brilaroxazine, or RP5063, is a novel, multimodal serotonin, dopamine & nicotinic receptors modulator with an improved efficacy & side effect profile compared to other antipsychotics. The agent provides a better balance of receptor activity that may allow for therapeutic doses to be used in difficult to treat patients while limiting the impact of the common neurological, metabolic and endocrine side effects associated with commonly prescribed agents.

3 Likes

Oh I remember that, it’s spent so long out of trials I thought they’d scrapped it. IIRC, it had a high rate of “remission level” response in the early studies.

Brilaroxazine, or RP5063, is a novel, multimodal serotonin, dopamine & nicotinic receptors modulator with an improved efficacy & side effect profile compared to other antipsychotics. The agent provides a better balance of receptor activity that may allow for therapeutic doses to be used in difficult to treat patients while limiting the impact of the common neurological, metabolic and endocrine side effects associated with commonly prescribed agents.

1 Like